PMID- 35479589 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220716 IS - 1108-7471 (Print) IS - 1792-7463 (Electronic) IS - 1108-7471 (Linking) VI - 35 IP - 2 DP - 2022 Mar-Apr TI - Clinical predictors of symptom improvement failure in gastroparesis. PG - 119-126 LID - 10.20524/aog.2022.0696 [doi] AB - BACKGROUND: The aim of this study was to determine clinical predictors of gastroparesis outcomes. METHODS: Between September 30, 2009 and January 31, 2020, we identified patients with gastroparesis diagnosed based on a (99m)Tc sulfur-labeled gastric emptying test. The patients who had no symptom improvement at 4 and 12 weeks were considered to have failed to show clinical improvement. Logistic regression was used to compute the association between different factors and clinical outcomes. RESULTS: We identified 320 patients (mean age 47.5+/-5.3 years, 70.3% female, 71.3% Whites). Failure of clinical improvement was seen in 34.7% patients at 4 weeks and 27.5% at 12 weeks after the gastroparesis diagnosis. At 4 weeks, chronic kidney disease (adjusted odds ratio [aOR] 2.62, 95% confidence interval [CI] 1.31-5.26; P=0.007) and body mass index (BMI) <18.5 kg/m(2) (aOR 9.90, 95%CI 2.98-32.93; P<0.001) were associated with a lack of improvement, whereas type 2 diabetes mellitus (T2DM) was associated with better clinical outcomes (aOR 0.50, 95%CI 0.25-0.99; P=0.047). At 12 weeks, subjects who had undergone post-bariatric surgery had no improvement of their gastroparesis symptoms (aOR 2.43, 95%CI 1.01-5.82; P=0.047), whereas T2DM was associated with clinical improvement (aOR 0.46, 95%CI 0.22-0.95; P=0.035). The subgroup analysis showed that BMI <18.5 kg/m(2) in non-diabetics and peripheral neuropathy in diabetics were associated with persistent symptoms. CONCLUSIONS: Gastroparesis patients with T2DM had significant symptom improvement. A history of bariatric surgery and renal failure were associated with worse clinical improvement. Peripheral neuropathy in diabetics was associated with persistent symptoms. CI - Copyright: (c) Hellenic Society of Gastroenterology. FAU - Amjad, Waseem AU - Amjad W AD - Internal Medicine, Albany Medical Center, Albany NY (Waseem Amjad, Asha Pandu, Muhammad Shabbir). AD - Clinical Research, Harvard Medical School, Boston MA (Waseem Amjad). FAU - Doycheva, Iliana AU - Doycheva I AD - Endocrinology and Metabolism, University of Chicago, Chicago IL (Iliana Doycheva). FAU - Kamal, Faisal AU - Kamal F AD - Gastroenterology and Hepatology, University of Tennessee, Memphis, TN (Faisal Kamal). FAU - Malik, Adnan AU - Malik A AD - Internal Medicine, Loyola University Medical Center, Chicago, IL (Adnan Malik). FAU - Pandu, Asha AU - Pandu A AD - Internal Medicine, Albany Medical Center, Albany NY (Waseem Amjad, Asha Pandu, Muhammad Shabbir). FAU - Shabbir, Muhammad Asim AU - Shabbir MA AD - Internal Medicine, Albany Medical Center, Albany NY (Waseem Amjad, Asha Pandu, Muhammad Shabbir). FAU - Mumtaz, Mirrah AU - Mumtaz M AD - Endocrinology, Albany Medical Center, Albany, NY (Mirrah Mumtaz). FAU - Batool, Asra AU - Batool A AD - Gastroenterology and Hepatology, Albany Medical Center, Albany, NY (Asra Batool). FAU - Ukleja, Andrew AU - Ukleja A AD - Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (Andrew Ukleja), USA. LA - eng PT - Journal Article DEP - 20220214 PL - Greece TA - Ann Gastroenterol JT - Annals of gastroenterology JID - 101121847 PMC - PMC8922264 OTO - NOTNLM OT - Gastroparesis OT - clinical outcomes OT - symptom improvement COIS- Conflict of Interest: None EDAT- 2022/04/29 06:00 MHDA- 2022/04/29 06:01 PMCR- 2022/03/01 CRDT- 2022/04/28 06:20 PHST- 2021/10/26 00:00 [received] PHST- 2022/01/17 00:00 [accepted] PHST- 2022/04/28 06:20 [entrez] PHST- 2022/04/29 06:00 [pubmed] PHST- 2022/04/29 06:01 [medline] PHST- 2022/03/01 00:00 [pmc-release] AID - AnnGastroenterol-35-119 [pii] AID - 10.20524/aog.2022.0696 [doi] PST - ppublish SO - Ann Gastroenterol. 2022 Mar-Apr;35(2):119-126. doi: 10.20524/aog.2022.0696. Epub 2022 Feb 14.